Monomethyl Fumarate Synthesis Using Solid Acid Catalyst
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing monomethyl fumarate result in contamination with impurities, particularly when using sulfuric acid as a catalyst, leading to the formation of genotoxic dimethyl sulfate, necessitating the development of alternative efficient methods for high-purity production.
Innovation Solution
A process involving the reaction of monomethyl maleate with a compound of formula (II), avoiding the use of aqueous media to minimize impurity formation, producing monomethyl fumarate in high yield and purity without toxic byproducts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If sulfuric acid is used as a catalyst in the preparation of monomethyl fumarate, then the reaction proceeds efficiently, but genotoxic dimethyl sulfate impurities are formed
Solution Approach 1:
The harmful sulfuric acid catalyst is completely removed from the process and replaced with a solid acid catalyst that can be easily separated. The reaction uses a solid acid catalyst (such as Amberlyst-15, Nafion, or sulfonated carbon) that can be filtered off after reaction, eliminating the source of dimethyl sulfate impurity formation while maintaining reaction efficiency
Solution Approach 2:
The invention employs a disposable solid acid catalyst that is used in one reaction and then discarded or regenerated. This single-use catalyst approach eliminates the need for complex catalyst recovery systems and ensures no residual catalyst remains in the final product, preventing impurity formation
2Ease of manufacture
If aqueous media is used in the reaction process, then the reaction can proceed, but impurity formation increases requiring further purification
Solution Approach 1:
The reaction medium is changed from aqueous to non-aqueous (such as dichloromethane, chloroform, or other organic solvents). This parameter change prevents hydrolysis reactions and formation of aqueous-phase impurities, while the organic solvent can be easily removed by evaporation, yielding high-purity product without requiring additional purification steps
Solution Approach 2:
The reaction is conducted in an inert organic solvent environment that does not participate in side reactions. This inert atmosphere prevents water-induced impurity formation and allows the reaction to proceed cleanly, with the solvent serving only as a reaction medium that can be completely removed afterward
3Manufacturing precision
If traditional purification methods are used to remove impurities, then product purity can be improved, but production time and cost increase
Solution Approach 1:
The reaction conditions are designed from the outset to prevent impurity formation rather than requiring subsequent purification. By using a solid acid catalyst and non-aqueous solvent system, the reaction produces minimal impurities that can be removed by simple filtration and solvent evaporation, eliminating the need for time-consuming chromatography or repeated recrystallization steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high-purity monomethyl fumarate production by eliminating aqueous media and volatile byproducts, reducing the need for further purification and avoiding toxic impurities like dimethyl sulfate.
Implementation Method 1
The reaction of monomethyl maleate with a compound of formula (II) to produce monomethyl fumarate
Data Source
AI summary
Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, inflammatory, and autoimmune diseases including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.